Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()

The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) early breast cancer (EBC) as recently demonstrated by the EBCTCTG metaanalysis on trastuzumab in HER2+ EBC: Adding trastuzumab to chemotherapy has reduced recurrence rates and breast-cancer r...

Descripción completa

Detalles Bibliográficos
Autor principal: Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097807/
https://www.ncbi.nlm.nih.gov/pubmed/35148934
http://dx.doi.org/10.1016/j.breast.2022.01.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097807/
https://www.ncbi.nlm.nih.gov/pubmed/35148934
http://dx.doi.org/10.1016/j.breast.2022.01.006

Ejemplares similares